Q4 EPS Forecast for Merit Medical Systems Lifted by Analyst

Key Points

• Zacks Research has raised its Q4 2025 earnings per share estimate for Merit Medical Systems to $0.82, up from a previous forecast of $0.75.
• Merit Medical Systems' latest quarterly earnings report exceeded expectations, with earnings per share of $1.01 and revenue of $382.46 million, marking a 13.2% increase year-over-year.
• The stock has received a consensus rating of "Moderate Buy" from analysts, with an average price target of $107.00 after various price adjustments by investment firms.

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Analysts at Zacks Research raised their Q4 2025 earnings per share (EPS) estimates for shares of Merit Medical Systems in a report released on Wednesday, August 20th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $0.82 for the quarter, up from their previous forecast of $0.75. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems' Q1 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.88 EPS, Q4 2026 earnings at $0.96 EPS and Q1 2027 earnings at $0.84 EPS.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.16. Merit Medical Systems had a net margin of 8.31% and a return on equity of 15.07%. The company had revenue of $382.46 million for the quarter, compared to analysts' expectations of $372.47 million. During the same period in the prior year, the business earned $0.92 earnings per share. Merit Medical Systems's revenue for the quarter was up 13.2% compared to the same quarter last year.

MMSI has been the subject of several other reports. Piper Sandler reduced their target price on Merit Medical Systems from $110.00 to $105.00 and set an "overweight" rating on the stock in a research note on Thursday, July 31st. Canaccord Genuity Group set a $112.00 price objective on Merit Medical Systems and gave the company a "buy" rating in a research report on Wednesday, May 21st. Barrington Research restated an "outperform" rating and issued a $103.00 target price on shares of Merit Medical Systems in a research report on Thursday, July 31st. Needham & Company LLC reiterated a "buy" rating and set a $108.00 price target on shares of Merit Medical Systems in a research report on Friday, July 18th. Finally, Raymond James Financial lowered their price objective on shares of Merit Medical Systems from $108.00 to $102.00 and set an "outperform" rating for the company in a report on Thursday, July 31st. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $107.00.

Merit Medical Systems Price Performance

Shares of NASDAQ:MMSI opened at $89.45 on Monday. The company's fifty day moving average price is $88.73 and its 200-day moving average price is $94.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.09 and a quick ratio of 2.66. The firm has a market capitalization of $5.30 billion, a price-to-earnings ratio of 45.41, a PEG ratio of 2.92 and a beta of 0.66. Merit Medical Systems has a one year low of $81.04 and a one year high of $111.45.

Insider Activity at Merit Medical Systems

In other Merit Medical Systems news, CEO Fred P. Lampropoulos sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $96.54, for a total transaction of $1,930,800.00. Following the completion of the transaction, the chief executive officer owned 1,066,028 shares of the company's stock, valued at $102,914,343.12. This represents a 1.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Raul Jr. Parra sold 15,181 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $93.75, for a total value of $1,423,218.75. Following the transaction, the chief financial officer directly owned 24,201 shares in the company, valued at $2,268,843.75. This trade represents a 38.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,779 shares of company stock worth $6,327,983 over the last 90 days. 3.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Merit Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of MMSI. Maseco LLP purchased a new stake in Merit Medical Systems in the second quarter worth about $28,000. Opal Wealth Advisors LLC bought a new stake in shares of Merit Medical Systems during the first quarter valued at approximately $31,000. IFP Advisors Inc grew its stake in Merit Medical Systems by 1,435.0% in the first quarter. IFP Advisors Inc now owns 307 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 287 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in Merit Medical Systems by 55.6% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 375 shares of the medical instruments supplier's stock worth $35,000 after purchasing an additional 134 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in Merit Medical Systems by 119.8% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 367 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 99.66% of the company's stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.